Primary Peritoneal Cavity Cancer Clinical Trial
Official title:
A Phase II Evaluation of Vorinostat, (SAHA, NCI-Supplied Agent [NSC #701852]) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Verified date | July 2019 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial is studying how well vorinostat works in treating patients with recurrent or persistent ovarian epithelial or primary peritoneal cavity cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Completed |
Enrollment | 60 |
Est. completion date | July 2008 |
Est. primary completion date | August 2006 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed ovarian epithelial or primary peritoneal cavity cancer - Recurrent or persistent disease - Disease progression during OR persistent disease after completion of 1 prior platinum-based chemotherapy regimen (containing carboplatin, cisplatin, or other organoplatinum compound) for primary disease - Initial treatment may have included high-dose, consolidation, noncytotoxic agents, or extended therapy administered after surgical or non-surgical assessment - Treatment-free interval after completion of platinum-based chemotherapy must have been < 12 months - Measurable disease, defined as = 1 unidimensionally measurable target* lesion = 20 mm by conventional techniques (e.g., palpation, plain x-ray, CT scan, or MRI) OR = 10 mm by spiral CT scan - Not eligible for a higher priority GOG protocol (i.e., any active phase III GOG protocol for the same patient population) - No known brain metastases - Performance status - GOG 0-1 - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Bilirubin = 1.5 times upper limit of normal (ULN) - SGOT = 2.5 times ULN - Alkaline phosphatase = 2.5 times ULN - Creatinine = 1.5 times ULN - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - Able to take oral medication - No bowel obstruction - No persistent vomiting - No parenteral feeding - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for = 1 month after completion of study treatment - No neuropathy (sensory and motor) > grade 1 - No other invasive malignancy within the past 5 years except nonmelanoma skin cancer - No active infection requiring antibiotics - No psychiatric illness or social situation that would preclude study compliance - No history of allergic reaction attributed to compounds of similar chemical or biological composition to vorinostat - No other uncontrolled illness - At least 4 weeks since prior immunotherapy for the malignancy - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) for the malignancy and recovered - No more than 2 prior cytotoxic chemotherapy regimens for recurrent or persistent disease - No prior non-cytotoxic chemotherapy for recurrent or persistent disease, unless therapy was part of the primary treatment regimen - No prior vorinostat - At least 1 week since prior hormonal therapy for the malignancy - Concurrent hormone replacement therapy allowed - At least 4 weeks since prior radiotherapy for the malignancy and recovered - No prior radiotherapy to > 25% of bone marrow - At least 4 weeks since prior surgery for the malignancy and recovered - At least 4 weeks since other prior therapy for the malignancy - At least 30 days since prior and no concurrent valproic acid - Concurrent oral anticoagulants (i.e., warfarin) allowed provided there is increased vigilance with respect to monitoring PT/INR for the first 2 courses of study therapy or if there are any signs of bleeding - No prior anticancer therapy that would preclude study participation - No concurrent combination anti-retroviral therapy for HIV-positive patients - No other concurrent investigational agents |
Country | Name | City | State |
---|---|---|---|
United States | Gynecologic Oncology Group | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | Gynecologic Oncology Group |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | Time at risk will be assessed from the date of registration onto the study and include all eligible patients who receive any study treatment. An analysis of any potential treatment effect on PFS may be conducted against the historical controls provided in GOG 126 and GOG 146 using a proportional hazards model that includes histological cell type, performance status, and platinum sensitivity. | At 6 months | |
Primary | Toxicity as assessed by CTCAE v 3.0 | Up to 5 years after completion of study treatment | ||
Secondary | Clinical response (partial and complete response) rate as according to RECIST s | Up to 5 years | ||
Secondary | Duration of PFS | From study entry until disease progression, death or date of last contact., assessed up to 5 years | ||
Secondary | Duration of survival | From entry into the study to death or the date of last contact, assessed up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Completed |
NCT00263822 -
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
|
Phase 3 | |
Terminated |
NCT00091195 -
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
|
Phase 2 | |
Completed |
NCT00075712 -
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00012090 -
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
|
Phase 2 | |
Completed |
NCT00003967 -
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
Completed |
NCT00019552 -
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT00003636 -
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
|
Phase 3 | |
Active, not recruiting |
NCT00003160 -
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
|
Phase 2 | |
Completed |
NCT00002538 -
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
|
Phase 2 | |
Completed |
NCT00002600 -
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT00838656 -
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT00093496 -
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
|
Phase 2 | |
Completed |
NCT00398138 -
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
|
Phase 1 | |
Completed |
NCT00049556 -
Gefitinib in Treating Patients With Cervical Cancer
|
Phase 2 | |
Terminated |
NCT00028782 -
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
|
N/A | |
Completed |
NCT00006942 -
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT00003670 -
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT00003998 -
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
|
Phase 3 | |
Completed |
NCT00003345 -
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
|
Phase 2 |